248 related articles for article (PubMed ID: 18042798)
1. Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease.
Levine JE; Paczesny S; Mineishi S; Braun T; Choi SW; Hutchinson RJ; Jones D; Khaled Y; Kitko CL; Bickley D; Krijanovski O; Reddy P; Yanik G; Ferrara JL
Blood; 2008 Feb; 111(4):2470-5. PubMed ID: 18042798
[TBL] [Abstract][Full Text] [Related]
2. Etanercept plus topical corticosteroids as initial therapy for grade one acute graft-versus-host disease after allogeneic hematopoietic cell transplantation.
Gatza E; Braun T; Levine JE; Ferrara JL; Zhao S; Wang T; Chang L; Harris A; Pawarode A; Kitko C; Magenau JM; Yanik GA; Couriel DR; Goldstein S; Connelly J; Reddy P; Paczesny S; Choi SW
Biol Blood Marrow Transplant; 2014 Sep; 20(9):1426-34. PubMed ID: 24892263
[TBL] [Abstract][Full Text] [Related]
3. Advances in the clinical management of GVHD.
Ferrara JL
Best Pract Res Clin Haematol; 2008 Dec; 21(4):677-82. PubMed ID: 19041607
[TBL] [Abstract][Full Text] [Related]
4. TNF-inhibition with etanercept for graft-versus-host disease prevention in high-risk HCT: lower TNFR1 levels correlate with better outcomes.
Choi SW; Stiff P; Cooke K; Ferrara JL; Braun T; Kitko C; Reddy P; Yanik G; Mineishi S; Paczesny S; Hanauer D; Pawarode A; Peres E; Rodriguez T; Smith S; Levine JE
Biol Blood Marrow Transplant; 2012 Oct; 18(10):1525-32. PubMed ID: 22469883
[TBL] [Abstract][Full Text] [Related]
5. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network.
Alousi AM; Weisdorf DJ; Logan BR; Bolaños-Meade J; Carter S; Difronzo N; Pasquini M; Goldstein SC; Ho VT; Hayes-Lattin B; Wingard JR; Horowitz MM; Levine JE;
Blood; 2009 Jul; 114(3):511-7. PubMed ID: 19443659
[TBL] [Abstract][Full Text] [Related]
6. Etanercept for steroid-refractory acute graft versus host disease following allogeneic hematopoietic stem cell transplantation.
Park JH; Lee HJ; Kim SR; Song GW; Lee SK; Park SY; Kim KC; Hwang SH; Park JS
Korean J Intern Med; 2014 Sep; 29(5):630-6. PubMed ID: 25228839
[TBL] [Abstract][Full Text] [Related]
7. [Use of monoclonal antibodies in prophylaxis and treatment of acute and chronic graft-versus-host disease in 2011].
Xhaard A; Hermet E; Bay JO; Peffault de Latour R
Bull Cancer; 2011 Aug; 98(8):889-99. PubMed ID: 21835730
[TBL] [Abstract][Full Text] [Related]
8. Anti-tumor necrosis factor-a for the treatment of steroid-refractory acute graft-versus-host disease.
Nogueira MC; Azevedo AM; Pereira SC; Ferreira JL; Lerner D; Lobo AM; Tavares RC; Tabak DG; Lorenzi N; Renault IZ; Bouzas LF
Braz J Med Biol Res; 2007 Dec; 40(12):1623-9. PubMed ID: 17713663
[TBL] [Abstract][Full Text] [Related]
9. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
[TBL] [Abstract][Full Text] [Related]
10. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
Busca A; Locatelli F; Marmont F; Ceretto C; Falda M
Am J Hematol; 2007 Jan; 82(1):45-52. PubMed ID: 16937391
[TBL] [Abstract][Full Text] [Related]
11. Combination antithymocyte globulin and soluble TNFalpha inhibitor (etanercept) +/- mycophenolate mofetil for treatment of steroid refractory acute graft-versus-host disease.
Kennedy GA; Butler J; Western R; Morton J; Durrant S; Hill GR
Bone Marrow Transplant; 2006 Jun; 37(12):1143-7. PubMed ID: 16699531
[TBL] [Abstract][Full Text] [Related]
12. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems.
MacMillan ML; Weisdorf DJ; Wagner JE; DeFor TE; Burns LJ; Ramsay NK; Davies SM; Blazar BR
Biol Blood Marrow Transplant; 2002; 8(7):387-94. PubMed ID: 12171485
[TBL] [Abstract][Full Text] [Related]
13. Combination Therapy for Graft-versus-Host Disease Prophylaxis with Etanercept and Extracorporeal Photopheresis: Results of a Phase II Clinical Trial.
Kitko CL; Braun T; Couriel DR; Choi SW; Connelly J; Hoffmann S; Goldstein S; Magenau J; Pawarode A; Reddy P; Schuler C; Yanik GA; Ferrara JL; Levine JE
Biol Blood Marrow Transplant; 2016 May; 22(5):862-8. PubMed ID: 26551636
[TBL] [Abstract][Full Text] [Related]
14. Pilot trial on the use of etanercept and methylprednisolone as primary treatment for acute graft-versus-host disease.
Uberti JP; Ayash L; Ratanatharathorn V; Silver S; Reynolds C; Becker M; Reddy P; Cooke KR; Yanik G; Whitfield J; Jones D; Hutchinson R; Braun T; Ferrara JL; Levine JE
Biol Blood Marrow Transplant; 2005 Sep; 11(9):680-7. PubMed ID: 16125638
[TBL] [Abstract][Full Text] [Related]
15. [Role of monoclonal antibodies in the treatment of acute graft versus host disease].
Bay JO; Cabrespine A; Peffault de Latour R
Bull Cancer; 2007 Jan; 94(1):33-41. PubMed ID: 17237003
[TBL] [Abstract][Full Text] [Related]
16. T cell costimulation blockade for hyperacute steroid refractory graft versus-host disease in children undergoing haploidentical transplantation.
Jaiswal SR; Zaman S; Chakrabarti A; Sehrawat A; Bansal S; Gupta M; Chakrabarti S
Transpl Immunol; 2016 Nov; 39():46-51. PubMed ID: 27577170
[TBL] [Abstract][Full Text] [Related]
17. Graft-versus-host disease treatment: predictors of survival.
Levine JE; Logan B; Wu J; Alousi AM; Ho V; Bolaños-Meade J; Weisdorf D;
Biol Blood Marrow Transplant; 2010 Dec; 16(12):1693-9. PubMed ID: 20541024
[TBL] [Abstract][Full Text] [Related]
18. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
Lee KH; Lee JH; Lee JH; Kim DY; Park HS; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Baek S; Kang YL; Kim SH; Yun SC; Kim H; Jo JC; Choi Y; Joo YD; Lim SN
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1555-1566. PubMed ID: 28552421
[TBL] [Abstract][Full Text] [Related]
19. [Influence of graft-versus-host disease on long-term survival of 26 patients with hematologic malignancies after transplantation].
Lin Q; Dong M; Wang QM; Wen JY; Wu XY
Ai Zheng; 2006 Oct; 25(10):1261-5. PubMed ID: 17059772
[TBL] [Abstract][Full Text] [Related]
20. Prognostic relevance of 'early-onset' graft-versus-host disease following non-myeloablative haematopoietic cell transplantation.
Mielcarek M; Burroughs L; Leisenring W; Diaconescu R; Martin PJ; Sandmaier BM; Maloney DG; Maris MB; Chauncey TR; Shizuru JA; Blume KG; Hegenbart U; Niederwieser D; Forman S; Bruno B; Woolfrey A; Storb R
Br J Haematol; 2005 May; 129(3):381-91. PubMed ID: 15842663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
